Novo Highlights CV Risks of Diabetes in Unbranded Campaign Featuring Anthony Anderson; Xeris Q1 ’22 Earnings Update

Two cardiometabolic-related news items have been observed: Novo has launched a new iteration of its “Get Real About Diabetes” campaign focusing on CV risk in T2DM (view article); and Xeris hosted its Q1 ‘22 earnings call (press release). Below, FENIX provides highlights and insights for the respective new items.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.